Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

Saved in:
Bibliographic Details
Published in:FEBS Open Bio
Format: Online Article RSS Article
Published: 2026
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1870568931061661696
collection WordPress RSS
FRELIP Feed Integration
container_title FEBS Open Bio
description
discipline_display Biochemistry
discipline_facet Biochemistry
format Online Article
RSS Article
genre Journal Article
id rss_article:102545
institution FRELIP
journal_source_facet FEBS Open Bio
last_indexed 2026-07-13T03:32:26.592Z
publishDate 2026
publishDateSort 2026
record_format rss_article
spellingShingle Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease
Biochemistry
General
Biochemistry
sub_discipline_display General
sub_discipline_facet General
subject_display Biochemistry
General
Biochemistry
subject_facet Biochemistry
General
Biochemistry
title Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease
title_alt El tratamiento con KCL‐286, un agonista del receptor de ácido retinoico β (RARβ) de primera clase, mejora el daño neuronal del ADN y la inflamación en un modelo de ratón con enfermedad de Alzheimer
Le traitement par KCL‐286, un agoniste de première classe du récepteur de l'acide rétinoïque β (RARβ), atténue les dommages à l'ADN neuronal et l'inflammation dans un modèle murin de la maladie d'Alzheimer
Tratamento com KCL‐286, um agonista do receptor de ácido retinoico β (RARβ) inovador, melhora o dano neuronal ao DNA e a inflamação em um modelo de camundongo da doença de Alzheimer
title_auth Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease
title_es_txt El tratamiento con KCL‐286, un agonista del receptor de ácido retinoico β (RARβ) de primera clase, mejora el daño neuronal del ADN y la inflamación en un modelo de ratón con enfermedad de Alzheimer
title_fr_txt Le traitement par KCL‐286, un agoniste de première classe du récepteur de l'acide rétinoïque β (RARβ), atténue les dommages à l'ADN neuronal et l'inflammation dans un modèle murin de la maladie d'Alzheimer
title_full Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease
title_fullStr Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease
title_full_unstemmed Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease
title_pt_txt Tratamento com KCL‐286, um agonista do receptor de ácido retinoico β (RARβ) inovador, melhora o dano neuronal ao DNA e a inflamação em um modelo de camundongo da doença de Alzheimer
title_short Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease
title_sort treatment with kcl‐286, a first‐in‐class retinoic acid receptor‐β (rarβ) agonist, ameliorates neuronal dna damage and inflammation in a mouse model of alzheimer's disease
topic Biochemistry
General
Biochemistry
url https://febs.onlinelibrary.wiley.com/doi/10.1002/2211-5463.70284?af=R